ReviewCurrent cardiology reports2026
Precision Medicine for Anticoagulation Strategies in the Cath Lab: Part 1.
Review in Current cardiology reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purpose of reviewIntraprocedural anticoagulation in the cardiac catheterization laboratory is essential to prevent thrombus formation on catheters, guidewires, and stents while minimizing bleeding risk. This review summarizes contemporary evidence and guideline recommendations for anticoagulation strategies during diagnostic catheterization and percutaneous coronary intervention (PCI). RECENT
findingsUnfractionated heparin (UFH) remains the standard intraprocedural agent, typically administered as a 50-100 U/kg intravenous bolus, and is routinely used during transradial access to prevent radial artery occlusion. Low-molecular-weight heparin (LMWH), particularly enoxaparin, provides more predictable factor Xa-mediated anticoagulation and is an alternative option for patients undergoing PCI in the settings of stable coronary artery disease (CAD), non-ST-segment elevation acute coronary syndrome (NSTE-ACS), and ST-segment elevation myocardial infarction (STEMI). Bivalirudin, a direct thrombin inhibitor, offers consistent anticoagulation independent of plasma cofactors and, particularly in STEMI, can be combined with a 2-4 h post-PCI infusion to reduce early stent thrombosis. Bivalirudin is an accepted alternative to UFH in both stable CAD and ACS, and is a preferred alternative to UFH to reduce mortality and major bleeding in STEMI (Class I recommendation), as well as in patients with heparin-induced thrombocytopenia or those at high bleeding risk. Fondaparinux has been associated with an increased risk of catheter-related thrombosis and therefore should not be used as a stand-alone intraprocedural anticoagulant during PCI. In PCI, contemporary randomized trials and guideline recommendations support UFH as standard therapy, with enoxaparin and bivalirudin as effective alternatives depending on clinical presentation and bleeding risk. Further studies are needed to refine anticoagulation strategies based on individualized risk factors and procedural context in contemporary PCI.
Indexed as
Identifiers
42430012What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.